FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, specifically to a pharmaceutical composition for the treatment or prevention of multiple sclerosis. The pharmaceutical composition includes non-immunogenic RNA encoding peptide or polypeptide containing an autoantigen. Non-immunogenic RNA becomes non-immunogenic due to inclusion of 1-methylpseudouridines and removal of dsRNA. Peptide or polypeptide encoded by non-immunogenic RNA contains an amino acid sequence of myelin-oligodendrocytic glycoprotein (MOG).
EFFECT: pharmaceutical composition induces tolerance to an autoantigen, and it can be used in medicine for the treatment or prevention of multiple sclerosis.
3 cl, 21 dwg, 11 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIGEN RECEPTORS AND THEIR APPLICATIONS | 2016 |
|
RU2792042C2 |
| INDIVIDUALISED VACCINES FOR CANCER | 2012 |
|
RU2670745C9 |
| INDIVIDUALIZED ANTI-TUMOR VACCINES | 2012 |
|
RU2779946C2 |
| 5'-CAP-TRINUCLEOTIDE COMPOUNDS OR 5'-CAP COMPOUNDS WITH LARGE NUMBER OF NUCLEOTIDES AND THEIR USE FOR RNA STABILIZATION, PROTEIN EXPRESSION AND IN THERAPY | 2019 |
|
RU2811940C2 |
| FORMULA FOR INTRODUCING RNA | 2019 |
|
RU2797147C2 |
| IMMUNOGENIC PEPTIDES FOR APPLICATION FOR PREVENTION AND/OR TREATMENT OF INFECTIOUS DISEASES, AUTOIMMUNE DISEASES, THE IMMUNE RESPONSES TO ALLOGENEIC FACTORS, ALLERGIC DISEASES, TUMOUR, TRANSPLANT REJECTION AND IMMUNE RESPONSES AGAINST VIRAL VECTORS USED FOR GENETIC THERAPY OR GENETIC VACCINATION | 2011 |
|
RU2615460C2 |
| METHODS AND COMPOSITIONS FOR STABLE IMMUNOTHERAPY | 2014 |
|
RU2696876C2 |
| ANTIGEN RECEPTORS AND THEIR APPLICATIONS | 2018 |
|
RU2794945C2 |
| COMPOSITION FOR RNA ADMINISTRATION | 2017 |
|
RU2746118C2 |
| ANTICANCER VACCINES TARGETING BORIS AND METHODS OF THEIR APPLICATION | 2018 |
|
RU2759681C1 |
